Full metadata record
DC FieldValueLanguage
dc.contributor.authorBornkamp, Björn-
dc.contributor.authorBretz, Frank-
dc.contributor.authorDette, Holger-
dc.contributor.authorJose, Pinheiro-
dc.date.accessioned2010-04-26T10:08:35Z-
dc.date.available2010-04-26T10:08:35Z-
dc.date.issued2010-04-26T10:08:35Z-
dc.identifier.urihttp://hdl.handle.net/2003/27121-
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-12670-
dc.description.abstractDose-finding studies are frequently conducted to evaluate the effect of different doses or concentration levels of a compound on a response of interest. Applications include the investigation of a new medicinal drug, a herbicide or fertilizer, a molecular entity, an environmental toxin, or an industrial chemical. In pharmaceutical drug development, dosefinding studies are of critical importance because of regulatory requirements that marketed doses are safe and provide clinically relevant efficacy. Motivated by a dose-finding study in moderate persistent asthma, we propose response-adaptive designs addressing two major challenges in dose-finding studies: uncertainty about the dose-response models and large variability in parameter estimates. To allocate new cohorts of patients in an ongoing study, we use optimal designs that are robust under model uncertainty. In addition, we use a Bayesian shrinkage approach to stabilize the parameter estimates over the successive interim analyses used in the adaptations. This allows us to calculate updated parameter estimates and model probabilities that can then be used to calculate the optimal design for subsequent cohorts. The resulting designs are hence robust with respect to model misspecification and additionally can efficiently adapt to the information accrued in an ongoing study. We focus on adaptive designs for estimating the minimum effective dose, although alternative optimality criteria or mixtures thereof could be used, enabling the design to address multiple objectives. In an extensive simulation study, we investigate the operating characteristics of the proposed methods under a variety of scenarios discussed by the clinical team to design the aforementioned clinical study.en
dc.language.isoenen
dc.relation.ispartofseriesDiscussion Paper / SFB 823;12/2010-
dc.subjectDose-responseen
dc.subjectDrug developmenten
dc.subjectMinimum effective doseen
dc.subjectOptimal designen
dc.subjectShrinkage approachen
dc.subject.ddc310-
dc.subject.ddc330-
dc.subject.ddc620-
dc.titleResponse-adaptive dose-finding under model uncertaintyen
dc.typeTextde
dc.type.publicationtypereportde
dcterms.accessRightsopen access-
Appears in Collections:Sonderforschungsbereich (SFB) 823

Files in This Item:
File Description SizeFormat 
DP_1210_SFB823_bornkamp_bretz_dette_pinheiro.pdfDNB261.37 kBAdobe PDFView/Open


This item is protected by original copyright



This item is protected by original copyright rightsstatements.org